The present invention relates to a structurally novel [1,2,4]triazolo[4,3-b][1,2,4]triazine compound represented by formula (I) or formula (II), a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate or solvate thereof. Also related to a preparation method of the compound, a pharmaceutical composition comprising an effective amount of the compound, as well as use of the compound as a protein tyrosine kinase inhibitor, particularly as a c-Met inhibitor, in the preparation of a medicament for the prevention and/or treatment of diseases associated with c-Met abnormality.